Pathological Diagnosis of Breast Cancer

Sachin B. Ingle
Department of Pathology, MIMSR Medical College, Latur, Maharashtra, India

Priti Katkade
Department of Pathology, Secretary Research & Development MIMSR Medical College, Vishwanathpuram, Latur-Maharashtra, India

Kundan Chavan
Department of Pathology, Secretary Research & Development MIMSR Medical College, Vishwanathpuram, Latur-Maharashtra, India

Datta Girji
Department of Pathology, Secretary Research & Development MIMSR Medical College, Vishwanathpuram, Latur-Maharashtra, India

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Clear

$95.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Breast tumors are one of the most worrisome and challenging problems for surgeons and pathologists. In this book, the authors present research in the study of the epidemiology, management and prevention of breast tumors; some examples of these types of breast cancer are DCIS, LCIS, IDC, ILC, medullary carcinoma, metaplastic carcinoma, papillary carcinoma, adenoid cystic carcinoma, and rare tumors of the breast. This book is useful to surgeons and pathologists, postgraduates in understanding the pathology for the diagnosis, treatment and prevention of these tumors. (Imprint: Nova Biomedical)

Preface

Chapter 1. Normal Histology of Breast

Chapter 2. WHO Classification of Breast Tumors

Chapter 3. Etiopathogenesis of Breast Cancer

Chapter 4. In situ Breast Cancer

Chapter 5. Lobular Carcinoma In situ

Chapter 6. Invasive Ductal Carcinoma (IDC- NOS)

Chapter 7. Invasive Lobular Carcinoma

Chapter 8. Medullary Carcinoma

Chapter 9. Metaplastic Carcinoma

Chapter 10. Adenoid Cystic Carcinoma (ACC) of Breast: An Unusual Breast Malignancy

Chapter 11. Papillary Carcinoma of Breast

Chapter 12. Rare Tumors of Breast

Index

Chapter 1

[1] Rosai Juan, Breast In: Rosai and Ackerman’s surgical pathology Volume-2, 10th Ed. Elsevier; 2012; 1660-1661.
[2] Kumar V, Abbas AK, Aster JC, et al; Breast In: Robbins &Cotran Pathologic Basis of Disease Volume-2, South Asia Ed. Elsevier; 2014; 1043-104.
[3] Mills SE, Carter D, Greenson JK, Reuter VE, Stoler MH, et al; Breast In: Sternberg’s Diagnostic Surgical Pathology Volume-1, 5th Ed. Wolter Kluwer/Lippincott Williams & Wilkins; 2010; 291-292.

Chapter 2

[1] Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007). “Overview of resistance to systemic therapy in patients with breast cancer.” Adv. Exp. Med. Biol. Advances in Experimental Medicine and Biology 608: 1–22. doi:10.1007/978-0-387-74039-3_1. ISBN 978-0-387-74037-9. PMID 17993229.
[2] Giordano SH, Hortobagyi GN (2003). “Inflammatory breast cancer: Clinical progress and the main problems that must be addressed.” Breast Cancer Res. 5 (6): 284–8. doi:10.1186/bcr608. PMC 314400. PMID 14580242.
[3] Merck Manual, Professional Edition, Ch. 253, Breast Cancer.
[4] Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 (invasive) and Table 3 (in situ) from Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (June 2009). “The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004.” Cancer Epidemiol. Biomarkers Prev. 18 (6): 1763–9. doi:10.1158/1055-9965. EPI-08-1082. PMID 19454615. These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer Facts & Figures 2003–2004 [1] [dead link].
[5] NOTE: Number really refers to invasive ductal carcinoma, despite title. Arpino G, Bardou VJ, Clark GM, Elledge RM (2004). “Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.” Breast Cancer Res. 6 (3): R149–56. doi:10.1186/bcr767. PMC 400666. PMID 15084238.
[6] Evans, A. (2004). “Ductal carcinoma in situ (DCIS): are we overdetecting it?”. Breast Cancer Research 6: P23. doi:10.1186/bcr842. [2].
[7] World Health Organization: Tumours of the Breast and Female Genital Organs. Oxford [Oxfordshire]: Oxford University Press. 2003. ISBN 92-832-2412-4.
[8] Elston CW, Ellis IO. Pathologic prognostic factors in breast cancer. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
[9] Bloom, H.J.; Richardson, W.W. (1957). “Histological grading and prognosis in breast cancer; A study of 1409 cases of which 359 have been followed for 15 years.” British Journal of Cancer 11 (3): 359–77. doi:10.1038/bjc.1957.43. PMC 2073885. PMID 13499785.
[10] Genestie, C.; Zafrani, B.; Asselain, B.; Fourquet, A.; Rozan, S.; Validire, P.; Vincent-Salomon, A.; Sastre-Garau, X. (1998). “Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems.” Anticancer Research 18 (1B): 571–6. PMID 9568179.
[11] National Comprehensive Cancer Network (NCCN) guidelines, Breast Cancer Version 2.2011 http://www.nccn.org/professionals/physician_ gls/pdf/breast.pdf.
[12] What is Cancer Staging? American Joint Committee on Cancer 2010 May 5.http://www.cancerstaging.org/mission/whatis.html.
[13] National Cancer Institute. Stage Information for Breast Cancer.http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/page3.
[14] American Joint Committee on Cancer. Past Editions of the AJCC Cancer Staging Manual available at http://www.cancerstaging.org/products/ pasteditions.html.
[15] AJCC Cancer Staging Manual, 7th edition, updated Cancer Staging Posters.http://www.cancerstaging.org/staging/posters/breast8.5x11.pdf.
[16] AJCC Cancer Staging Manual 6th edition; Chapter 25; Breast Cancer – original pages 223-240 http://www.cancerstaging.org/products/ csmanual6ed-4.pdf.
[17] AJCC Cancer Staging Manual 5th edition; Chapter 25; Breast Cancer – original pages 171-180 http://www.cancerstaging.org/products/ csmanual5ed_4.pdf.
[18] AJCC Cancer Staging Manual 4th edition; Chapter 25; Breast Cancer – original pages 149-154 http://www.cancerstaging.org/products/ csmanual4ed_2.pdf.
[19] AJCC Cancer Staging Manual 3rd edition; 1988; Chapter 23; Breast Cancer-original pages 145-150 http://www.cancerstaging.org/products/ csmanual3ed_2.pdf.
[20] AJCC Cancer Staging Manual 2nd edition; 1983; Chapter 21; Breast Cancer-original pages 127-134 http://www.cancerstaging.org/products/ csmanual2ed.pdf.
[21] AJCC Cancer Staging Manual 1977; Chapter 12; Breast Cancer-original pages 101-108 http://www.cancerstaging.org/products/csmanual1ed.pdf.
[22] Feinstein, A. R.; Sosin, D. M.; Wells, C. K. (1985). “The Will Rogers Phenomenon.” New England Journal of Medicine 312 (25): 1604–1608. doi:10.1056/NEJM198506203122504. PMID 4000199.
[23] Woodward, W. A.; Strom, E. A.; Tucker, S. L.; McNeese, M. D.; Perkins, G. H.; Schechter, N. R.; Singletary, S. E.; Theriault, R. L.; Hortobagyi, G. N.; Hunt, K. K.; Buchholz, T. A. (2003). “Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer Dramatically Affect Stage-Specific Survival.” Journal of Clinical Oncology 21 (17): 3244–3248. doi:10.1200/JCO.2003.03.052. PMID 12947058.
[24] Scatarige JC, Fishman EK, Zinreich ES, Brem RF, Almaraz R (April 1988). “Internal mammary lymphadenopathy in breast carcinoma: CT appraisal of anatomic distribution.” Radiology 167 (1): 89–91. doi:10.1148/radiology.167.1.3347753. PMID 3347753.
[25] Scatarige JC, Boxen I, Smathers RL (September 1990). “Internal mammary lymphadenopathy: imaging of a vital lymphatic pathway in breast cancer.” Radiographics 10 (5): 857–70. doi:10.1148/ radiographics.10.5.2217975. PMID 2217975. available as full text article with multiple images at http://radiographics.rsna.org/content/ 10/5/857.full.pdf.
[26] Kumar, V; Abbas, AK; Fausto, N; Mitchell, R. “19 – The Female Genital System and Breast.” Robbins Basic Pathology. (8th ed.). p. 749. ISBN 1416029737.
[27] Molecular origin of cancer: gene-expression signatures in breast cancer, Christos Sotirou and Lajos Pusztai, N Engl J Med 360:790 (2009 Feb 19).
[28] Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2+ breast cancer. N Engl J Med. 2005; 353:1673-1684 and supplementary appendix.
[29] Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK; et al. (2007-08-01). “Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence.” Clinical Cancer Research (American Association for Cancer Research) 13 (15 Pt 1): 4429–4434. doi:10.1158/1078-0432.CCR-06-3045. PMID 17671126.
[30] “Understanding and Treating Triple-Negative Breast Cancer.” Cancer Network. Retrieved 2010-05-08.
[31] Lehmann, B. D.; Bauer, J. A.; Chen, X.; Sanders, M. E.; Chakravarthy, A. B.; Shyr, Y.; Pietenpol, J. A. (2011). “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.” Journal of Clinical Investigation 121 (7): 2750–2767. doi:10.1172/JCI45014. PMC 3127435. PMID 21633166.
[32] Hu, R.; Dawood, S.; Holmes, M. D.; Collins, L. C.; Schnitt, S. J.; Cole, K.; Marotti, J. D.; Hankinson, S. E.; Colditz, G. A.; Tamimi, R. M. (2011). “Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women.” Clinical Cancer Research 17 (7): 1867–1874. doi:10.1158/1078-0432.CCR-10-2021. PMC 3076683. PMID 21325075.
[33] Prat, A.; Perou, C. M. (2011). “Deconstructing the molecular portraits of breast cancer.” Molecular Oncology 5 (1): 5–23. doi:10.1016/j.molonc. 2010.11.003. PMID 21147047.
[34] Geyer, F. C.; Marchiò, C.; Reis-Filho, J. S. (2009). “The role of molecular analysis in breast cancer.” Pathology 41 (1): 77–88. doi:10.1080/00313020802563536. PMID 19089743.
[35] Perou, C. M. (2011). “Molecular Stratification of Triple-Negative Breast Cancers.” The Oncologist 16: 61–70. doi:10.1634/theoncologist.2011-S1-61.
[36] Ross, J. S. (2009). “Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome.” Advances in Anatomic Pathology 16 (4): 204–215. doi:10.1097/PAP.0b013e3181a9d4bf. PMID 19546609.
[37] Herschkowitz, J. I.; Zhao, W.; Zhang, M.; Usary, J.; Murrow, G.; Edwards, D.; Knezevic, J.; Greene, S. B.; Darr, D.; Troester, M. A.; Hilsenbeck, S. G.; Medina, D.; Perou, C. M.; Rosen, J. M. (2011). “Breast Cancer Special Feature: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.” Proceedings of the National Academy of Sciences 109 (8): 2778. doi:10.1073/pnas. 1018862108.
[38] Harrell, J. C.; Prat, A.; Parker, J. S.; Fan, C.; He, X.; Carey, L.; Anders, C.; Ewend, M.; Perou, C. M. (2011). “Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.” Breast Cancer Research and Treatment 132 (2): 523–535. doi:10.1007/s10549-011-1619-7. PMC 3303043. PMID 21671017.
[39] Perou CM, Sørlie T, Eisen MB; et al. (August 2000). “Molecular portraits of human breast tumours.” Nature 406 (6797): 747–52. doi:10.1038/35021093. PMID 10963602.
[40] Nagasaki K, Miki Y (2006). “Gene expression profiling of breast cancer.” Breast Cancer 13 (1): 2–7. doi:10.2325/jbcs.13.2. PMID 16518 056.
[41] Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A (2009). “Prognostic applications of gene expression signatures in breast cancer.” Oncology. 77 Suppl 1: 2–8. doi:10.1159/000258489. PMID 20130425.
[42] Jönsson G, Staaf J, Vallon-Christersson J; et al. (2010). “Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.” Breast Cancer Res. 12 (3): R42. doi:10.1186/bcr2596. PMC 2917037. PMID 20576095.
[43] Sparano JA, Solin LJ (April 2010). “Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making.” J. Clin. Oncol. 28 (10): 1625–7. doi:10.1200/JCO.2009.25.2882. PMID 20065178.
[44] Mandrekar SJ, Sargent DJ (October 2010). “Predictive biomarker validation in practice: lessons from real trials.” Clin Trials 7 (5): 567–73. doi:10.1177/1740774510368574. PMID 20392785.
[45] Pharoah PD, Caldas C (November 2010). “Genetics: How to validate a breast cancer prognostic signature.” Nat Rev Clin Oncol 7 (11): 615–6. doi:10.1038/nrclinonc.2010.142. PMID 20981123.
[46] Ross, J. S.; Hatzis, C.; Symmans, W. F.; Pusztai, L.; Hortobagyi, G. N. (2008). “Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer.” The Oncologist 13 (5): 477–493. doi:10.1634/ theoncologist.2007-0248. PMID 18515733.
[47] Albain, K. S.; Paik, S.; Van't Veer, L. (2009). “Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.” The Breast 18: S141–S145. doi:10.1016/S0960-9776(09)70290-5. PMID 19914534.
[48] Fan, C.; Oh, D. S.; Wessels, L.; Weigelt, B.; Nuyten, D. S. A.; Nobel, A. B.; Van't Veer, L. J.; Perou, C. M. (2006). “Concordance among Gene-Expression–Based Predictors for Breast Cancer.” New England Journal of Medicine 355 (6): 560–569. doi:10.1056/NEJMoa052933. PMID 16899776.
[49] Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast Jr, R. C.; American Society of Clinical Oncology (2007). “American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.” Journal of Clinical Oncology 25 (33): 5287–5312. doi:10.1200/JCO.2007.14.2364. PMID 17954709.
[50] Armen Hareyanon. MapQuant Dx Genomic Grade Test Identifies Breast Cancer Patients. 2008-06-02 http://www.emaxhealth.com/98/22731. html.
[51] Filho, O. M.; Ignatiadis, M.; Sotiriou, C. (2011). “Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.” Critical Reviews in Oncology/Hematology 77 (1): 20–29. doi:10.1016/j.critrevonc.2010.01.011. PMID 20138540.
[52] “Select your country: Qiagen Marseille” (PDF). ipsogen.com. Retrieved 12 December 2015.[dead link].
[53] Gianni L, Zambetti M, Clark K; et al. (October 2005). “Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.” J. Clin. Oncol. 23 (29): 7265–77. doi:10.1200/JCO.2005.02.0818. PMID 16145055.
[54] Kelly CM, Krishnamurthy S, Bianchini G; et al. (November 2010). “Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.” Cancer 116 (22): 5161–7. doi:10.1002/cncr. 25269. PMID 20665886.
[55] Lo, S. S.; Mumby, P. B.; Norton, J.; Rychlik, K.; Smerage, J.; Kash, J.; Chew, H. K.; Gaynor, E. R.; Hayes, D. F.; Epstein, A.; Albain, K. S. (2010). “Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection.” Journal of Clinical Oncology 28 (10): 1671–1676. doi:10.1200/JCO.2008.20.2119. PMID 20065191.
[56] Albanell, J.; González, A.; Ruiz-Borrego, M.; Alba, E.; García-Saenz, J. A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limon, M. L.; Muñoz, A. S.; Martín, M.; Tusquets, I.; Rojo, F.; Colomer, R.; Faull, I.; Lluch, A. (2011). “Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.” Annals of Oncology 23 (3): 625–631. doi:10.1093/annonc/mdr278. PMID 21652577.
[57] New Mexico OncologyHematology Consultants, Ltd. Copyright held by CancerConsultants Breast Cancer Information Center. European Study Reports that Oncotype DX Influences Breast Cancer Treatment Decisions. Posted 2010 October 17, accessioned 2010 Dec 19 and 2011 July 03 at http://nmcancercenter.org/european-study-reports-that-oncotype-dx%C2%AE-influences-breast-cancer-treatment-decisions/.
[58] Tice JA. The 70-Gene Signature (MammaPrint) as a Guide for the Management of Early Stage Breast Cancer. California Technology Assessment Forum. 2010 June 2nd. Full text accessioned 2010 Dec 19 at http://www.ctaf.org/content/assessments/detail/?id=1178.
[59] NCI Cancer Bulletin FDA Update 2007 February 14, Volume 4, Number 7 as retrieved 2010 October 17 at http://www.cancer.gov/aboutnci/ ncicancerbulletin/archive/2007/021407/page5.
[60] The mission of Agendia. Agendia web site.http://www.agendia.com/ pages/mission/86.php.
[61] Ordering Symphony is a simple process. Agendia web site.http:// www.agendia.com/pages/ordering_symphony/38.php.
[62] MammaPrint Patient Eligibility Internationally (Outside of the USA) http://www.agendia.com/pages/patient_eligibility_internationally/317. php.
[63] Introducing BluePrint: A Molecular Subtyping Profile for Breast Cancer. Agendia web site.http://www.agendia.com/pages/blueprint/324.php.
[64] DNA topoisomerase II alfa expression and the response to primary chemotherapy in breast cancer. MacGrogan G et al. British Journal of Cancer 2003; 89: 666–671. doi:10.1038/sj.bjc.6601185 www.bjcancer. com.
[65] Gene Review TOP2A – topoisomerase (DNA) II alpha 170kDa Homo sapiens as retrieved 2010 October 18 http://www.wikigenes.org/ e/gene/e/7153.html.
[66] Alvarez, R. H.; Valero, V.; Hortobagyi, G. N. (2010). “Emerging Targeted Therapies for Breast Cancer.” Journal of Clinical Oncology 28 (20): 3366–3379. doi:10.1200/JCO.2009.25.4011. PMID 20530283.
[67] Tutt A J Clin Onc 2009; 27(suppl 15): abst CRA501.
[68] Issaeva N, Thomas HD, Djureinovic T; et al. (August 2010). “6-thioguanine selectively kills BRCA2 defective tumours and overcomes PARP inhibitor resistance.” Cancer Res. 70 (15): 6268–76. doi:10.1158/0008-5472.CAN-09-3416.PMC 2913123.PMID 206310 63.Correction published at Correction: 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance Cancer Res 2010 October 1;70:7734.
[69] Baselga J et al. J Clin Oncol 2009; 27: 2630–2637.
[70] D'Anello L, Sansone P, Storci G; et al. (2010). “Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells.” Mol. Cancer 9: 300. doi:10.1186/1476-4598-9-300. PMC 3002335. PMID 21092249.
[71] Liu, C. -C.; Prior, J.; Piwnica-Worms, D.; Bu, G. (2010). “LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.” Proceedings of the National Academy of Sciences 107 (11): 5136–5141. doi:10.1073/pnas.0911220107. PMC 2841938. PMID 2019 4742.
[72] Rae JM, Drury S, Hayes DF et al. Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. 33rd Annual San Antonio Breast Cancer Symposium (SABCS): abstract S1-7 presented 2010 December 9; accessioned 2010 December 17 at http://www.abstracts2view.com/sabcs10/view.php? nu=SABCS10L_1093&terms=.
[73] Leyland-Jones B, Regan MM, Bouzyk M et al. Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial. 33rd Annual San Antonio Breast Cancer Symposium (SABCS): abstract S1-8 presented 2010, December 9; accessioned 2010 December 17 at http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS 10L_556&terms=.
[74] Ruiter R; Bijl MJ; van Schaik RHN et al. CYP2C19*2 Polymorphism is Associated with Increased Survival in Breast Cancer Patients Using Tamoxifen. Pharmacogenomics. 2010;11(10):1367–1375.
[75] Jerevall P; Jansson A; Fornander T et al. Predictive Relevance of HOXB13 Protein Expression for Tamoxifen Benefit in Breast Cancer. Breast Cancer Research. 2010;12(206).
[76] “Study sheds new light on tamoxifen resistance.” CORDIS: News. 2008-11-13. Hurtado A, Holmes KA, Geistlinger TR; et al. (December 2008). “ERBB2 regulation by Estrogen Receptor-Pax2 determines tamoxifen response.” Nature 456 (7222): 663–6. doi:10.1038/nature 07483. PMC 2920208. PMID 19005469.
[77] Mc Ilroy M, Fleming FJ, Buggy Y, Hill AD, Young LS (December 2006). “Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.” Endocr. Relat. Cancer 13 (4): 1135–45. doi:10.1677/erc.1.01222. PMID 17158759.
[78] Spears M, Bartlett J (June 2009). “The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.” Expert Opin. Ther. Targets 13 (6): 665–74. doi:10.1517/1472 8220902911509. PMID 19456271.
[79] [3][dead link].
[80] Ravdin PM, Siminoff LA, Davis GJ; et al. (February 2001). “Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.” J. Clin. Oncol. 19 (4): 980–91. PMID 11181660.
[81] Olivotto IA, Bajdik CD, Ravdin PM; et al. (April 2005). “Population-based validation of the prognostic model ADJUVANT! for early breast cancer.” J. Clin. Oncol. 23 (12): 2716–25. doi:10.1200/JCO. 2005.06. 178. PMID 15837986.
[82] Mook S, Schmidt MK, Rutgers EJ; et al. (November 2009). “Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.” Lancet Oncol. 10 (11): 1070–6. doi:10.1016/S1470-2045(09) 70254-2. PMID 19801202.
[83] Campbell HE, Taylor MA, Harris AL, Gray AM (October 2009). “An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom.” Br. J. Cancer 101 (7): 1074–84. doi:10.1038/sj.bjc.6605283. PMC 2768087. PMID 19724274.
[84] Wishart GC, Azzato EM, Greenberg DC; et al. (2010). “PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.” Breast Cancer Res. 12 (1): R1. doi:10.1186/ bcr2464. PMC 2880419. PMID 20053270.
[85] Dawson SJ, Makretsov N, Blows FM; et al. (August 2010). “BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.” Br. J. Cancer 103 (5): 668–75. doi:10.1038/sj.bjc.6605736. PMC 2938244. PMID 20664598.
[86] Choosing Treatment for Patients With Ductal Carcinoma In Situ: Fine Tuning the University of Southern California/Van Nuys Prognostic Index Melvin J. Silverstein and Michael D. Lagios J Natl Cancer Inst Monogr (2010)2010 (41): 193-196. doi:10.1093/jncimonographs/lgq040.

Chapter 3

[1] Gail MH, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879.
[2] Gail MH, et al: Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007; 99:1782.
[3] Russo J, et al: Full-term pregnancy induces a specific genomic signature in the human breast. Cancer Epidemiol Biomarkers Prev 2008; 17:51.
[4] Schedin P: Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006; 4:281.
[5] Morris CR, et al: The risk of developing breast cancer within the next 5, 10, or 20 years of a woman's life. Am J Prev Med 2001; 20:213.
[6] Hayanga AJ, Newman LA: Investigating the phenotypes and genotypes of breast cancer in women with African ancestry: the need for more genetic epidemiology. Surg Clin North Am 2007; 87:551.
[7] Rossouw JE, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.
[8] Beral VCollaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 2002; 360:187.
[9] American Institute for Cancer Research/World Cancer Research Fund, Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective.
[10] Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC (October 2010). “Physical activity and risk of breast cancer among postmenopausal women.” Arch. Intern. Med. 170 (19): 1758–64. doi:10.1001/archinternmed.2010.363. PMC 3142573. PMID 20975025.
[11] Zheng JS, Hu XJ, Zhao YM, Yang J, Li D (2013). “Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies.” BMJ 346: f3706. doi:10.1136/bmj.f3706. PMID 23814120.
[12] Wu, AH; Yu, MC; Tseng, CC; Pike, MC (15 January 2008). “Epidemiology of soy exposures and breast cancer risk.” British journal of cancer 98 (1): 9–14. doi:10.1038/sj.bjc.6604145. PMID 18182974.
[13] “SEER Stat Fact Sheets: Breast Cancer.” NCI. Retrieved 18 June 2014.
[14] Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB (1999). “Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.” N Engl J Med 340 (2): 77–84. doi:10.1056/NEJM199901143400201. PMID 9887158.
[15] Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG (2001). “Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutations.” N Engl J Med 345 (3): 159–164. doi:10.1056/NEJM200107193450301. PMID 11463009.
[16] Lostumbo, L; Carbine, NE; Wallace, J (10 November 2010). “Prophylactic mastectomy for the prevention of breast cancer.” The Cochrane database of systematic reviews (11): CD002748. doi:10.1002/14651858.CD002748.pub3. PMID 21069671.
[17] “Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.” Annals of Internal Medicine 160: 271–281. 24 December 2013. doi:10.7326/M13-2747.
[18] Nelson HD, Smith ME, Griffin JC, Fu R (16 April 2013). “Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.” Annals of Internal Medicine 158 (8): 604–14. doi:10.7326/0003-4819-158-8-201304160-00005. PMID 23588749.
[19] Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL (25 May 2013). “Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.” Lancet 381 (9880): 1827–34. doi:10.1016/S0140-6736(13)60140-3. PMID 2363 9488.
[20] Moyer VA (24 September 2013). “Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.” Annals of Internal Medicine. doi:10.7326/0003-4819-159-10-201311190-00718. PMID 24061472.
[21] Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL (31 March 2013). “Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.” The Lancet 381 (9880): 1827–34. doi:10.1016/S0140-6736(13)60140-3. PMID 23639488.
[22] Bradbury AR, Olopade OI: Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 2007; 8:225.
[23] Garcia-Closas M, et al: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLOS Genetics 2008; 4:e10000054.
[24] Pageau GJ, et al: The disappearing Barr body in breast and ovarian cancers. Nat Rev Cancer 2007; 7:628.
[25] Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354:270.
[26] Desta Z, Flockhart DA: Germline pharmacogenetics of tamoxifen response: have we learned enough?. J Clin Oncol 2007; 25:5147.
[27] Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100:57.
[28] Hahn WC, Weinberg RA: Rules for making human tumor cells. N Engl J Med 2002; 347:1593.
[29] Iqbal M, et al: Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells. J Pathol 2001; 193:333.
[30] Campbell LL, Polyak K: Breast tumor heterogeneity. Cancer stem cells or clonal evolution?. Cell Cycle 2007; 6:2332.
[31] Stingl J, Caldas C: Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007; 10:791.
[32] Murad TM: A proposed histochemical and electron microscopic classification of human breast cancer according to cell of origin. Cancer 1971; 27:288.
[33] Shipitisin M, et al: Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11:259.
[34] Gauthier ML, et al: Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007; 12:479.
[35] Tlsty T, Coussens LM: Tumor stroma and regulation of cancer development. Ann Rev Pathol Mech Dis 2006; 1:119.
[36] Patocs A, et al: Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357:2543.
[37] Allred DC, et al: Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008; 14:370.
[38] Wiseman BS, Werb Z: Stromal effects on mammary gland development and breast cancer. Science 2002; 296:1046.

Chapter 4

[1] Sinn, HP; Kreipe, H (May 2013). “A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition.” Breast care (Basel, Switzerland) 8 (2): 149–154. doi:10.1159/000350774. PMID 24415964.
[2] Seltzer, William H. Hindle, editor; with a foreword by Vicki (1999). Breast care: a clinical guidebook for women's primary health care providers. New York: Springer. p. 129. ISBN 9780387983486.
[3] Staging, Breastcancer.org.
[4] Welch HG, Woloshin S, Schwartz LM (February 2008). “The sea of uncertainty surrounding ductal carcinoma in situ--the price of screening mammography.” J. Natl. Cancer Inst. 100 (4): 228–9. doi:10.1093/jnci/ djn013. PMID 18270336.
[5] Liberman, Laura (2005). Breast MRI. [New York]: Springer Science+Business Media, Inc. p. 164. ISBN 9780387219974.
[6] Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ (September 2009). “Diagnosis and management of ductal carcinoma in situ (DCIS).” Evidence Report/Technology Assessment. AHRQ Publication No.09-E018. (185): 1–549. PMID 20629475.
[7] Rubin's Pathology: clinicopathologic foundations of medicine (5. ed.). Philadelphia [u.a.]: Wolters Kluwer/Lippincott Williams & Wilkins. 2008. p. 848. ISBN 9780781795166. |first1= missing |last1= in Authors list (help)
[8] “Breast Cancer Treatment (PDQ®).” NCI. 2014-04-11. Retrieved 19 June 2014.
[9] “Breast Cancer Treatment (PDQ®).” NCI. Retrieved 19 June 2014.
[10] Allred DC (2010). “Ductal carcinoma in situ: terminology, classification, and natural history.” Journal of the National Cancer Institute. Monographs 2010 (41): 134–8. doi:10.1093/jncimonographs/ lgq035. PMID 20956817.
[11] Padwal, David Hui (2011). Alexander Leung and Raj Padwal, ed. Approach to internal medicine a resource book for clinical practice (3rd ed.). New York: Springer. p. 198. ISBN 9781441965059.
[12] Tjandra, Joe J.; Collins, John P. (2006). “Breast surgery.” In Tjandra; et al. Textbook of surgery (3rd ed.). Malden, Mass.: Blackwell Pub. p. 282. ISBN 9780470757796.
[13] Chang, Alfred (2007). Oncology: An Evidence-Based Approach. Springer. p. 162. ISBN 9780387310565.
[14] J.@Saclarides, ed. by Jonathan A.@Myers, Keith W.@Millikan, Theodore (2008). Common surgical diseases an algorithmic approach to problem solving. (2nd rev. ed.). New York: Springer. ISBN 9780387752464.
[15] “Breast Cancer.” Retrieved 2010-06-28.
[16] “Signs and Symptoms.” Retrieved 2010-06-28.
[17] “After the mammogram.” Retrieved 2010-06-28.
[18] “Intraductal Carcinoma of the Breast.” Retrieved 2010-06-28.
[19] “Ductal Carcinoma In Situ.” cancer.gov. January 9, 2015. Retrieved 5 March 2015.
[20] “Ductal Carcinoma In Situ: Treatment Options for Patients With DCIS.” National Cancer Institute at NIH. National Institutes of Health. 2014-07-11.
[21] “Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.” Prescrire Int 144 (22): 298–303. Dec 2013. PMID 24600734.
[22] Ductal Carcinoma in Situ (DCIS), Johns Hopkins Medicine.
[23] Goodwin A, Parker S, Ghersi D, Wilcken N (2013). “Post-operative radiotherapy for ductal carcinoma in situ of the breast.” The Cochrane Database of Systematic Reviews 11: CD000563. doi:10.1002/14651858. CD000563.pub7. PMID 24259251.
[24] Virnig, BA; Tuttle, TM; Shamliyan, T; Kane, RL (2010). “Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.” Journal of the National Cancer Institute 102 (3): 170–8. doi:10.1093/jnci/djp482. PMID 20071685.
[25] “NIH DCIS Consensus Conference Statement.” National Institutes of Health. September 2009.
[26] Virnig, BA; Shamliyan, T; Tuttle, TM; Kane, RL; Wilt, TJ (September 2009). “Diagnosis and management of ductal carcinoma in situ (DCIS).” Evidence report/technology assessment (185): 4. PMID 20629475. They found women undergoing mastectomy were less likely than women undergoing lumpectomy plus radiation to experience local DCIS or invasive recurrence. Women undergoing BCS alone were also more likely to experience a local recurrence than women treated with mastectomy. We found no study showing a mortality reduction associated with mastectomy over breast conserving surgery with or without radiation.
[27] “Intraductal carcinoma.” Retrieved 2010-06-28.
[28] Tan JC, McCready DR, Easson AM, Leong WL (February 2007). “Role of sentinel lymph node biopsy in ductal carcinoma-in-situ treated by mastectomy.” Annals of Surgical Oncology 14 (2): 638–45. doi:10.1245/s10434-006-9211-9. PMID 17103256.
[29] van Deurzen CH, Hobbelink MG, van Hillegersberg R, van Diest PJ (April 2007). “Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review.” European Journal of Cancer 43 (6): 993–1001. doi:10.1016/j.ejca.2007.01.010. PMID 17300928.
[30] Kerlikowske, K (2010). “Epidemiology of ductal carcinoma in situ.” Journal of the National Cancer Institute. Monographs 2010 (41): 139–41. doi:10.1093/jncimonographs/lgq027. PMID 20956818.
[31] Kerlikowske, K.; Molinaro, A. M.; Gauthier, M. L.; Berman, H. K.; Waldman, F.; Bennington, J.; Sanchez, H.; Jimenez, C.; Stewart, K.; et al. (2010). “Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma in Situ Diagnosis.” JNCI Journal of the National Cancer Institute 102 (9): 627–637. doi:10.1093/jnci/djq101. PMC 2864293. PMID 20427430.
[32] Witkiewicz AK, Dasgupta A, Nguyen KH, et al. (June 2009). “Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer.” Cancer Biology & Therapy 8 (11): 1071–1079. doi:10.4161/ cbt.8.11.8874. PMID 19502809.
[33] “Intraductal carcinoma.” Retrieved 2010-06-28.
[34] Rosai Juan,Breast In: Rosai and Ackerman’s surgical pathology Volume-2, 10th Ed. Elsevier; 2012; 1689-1694.
[35] Orell SR, Sterrett GF, et al; Breat In: Orell and Sterret’s Fine Needle Aspiration Cytology, 5th Ed. Elsevier; 2012; 188.
[36] Frost AR, Aksu A, Kurstin R, et al. Can nonproliferative breast disease and proliferative breast disease without atypia be distinguished by fine – needle aspiration cytology? Cancer 1997;81:22-8.

Chapter 5

[1] “Lobular Carcinoma in situ (LCIS).” Breast Cancer. Stanford Cancer Center.
[2] “Lobular carcinoma in situ: Marker for breast cancer risk.” MayoClinic.com.
[3] “Breast Cancer Treatment.” National Cancer Institute.
[4] Afonso N, Bouwman D (August 2008). “Lobular carcinoma in situ.” Eur. J. Cancer Prev. 17 (4): 312–6. doi:10.1097/CEJ.0b013e32 82f75e5d. PMID 18562954.
[5] Cancer, American Joint Committee on (2002). AJCC cancer staging handbook: from the AJCC cancer staging manual (6th ed.). New York: Springer. p. 260. ISBN 9780387952703.
[6] “Susan G. Komen for the Cure | Understanding Breast Cancer | Breast Facts | Statistics | Breast Cancer Statistics.” Retrieved 2013-01-16.
[7] Hajra KM, Fearon ER (2002). “Cadherin and catenin alterations in human cancer.” Genes Chromosomes Cancer 34 (3): 255–68. doi:10.1002/gcc.10083. PMID 12007186.
[8] Lakhani SR (2001). “Molecular genetics of solid tumors: translating research into clinical practice. What we could do now: breast cancer.” Mol Pathol 54 (5): 281–4. doi:10.1136/mp.54.5.281. PMC 1187082. PMID 11577167.
[9] Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, MO: Elsevier Saunders. p. 1142. ISBN 0-7216-0187-1.
[10] “Breast Cancer Treatment (PDQ®) - National Cancer Institute - Lobular Carcinoma In Situ.” Retrieved 2013-01-12.
[11] Page DL, Schuyler PA, DuPont WD, Jensen RA, Plummer WD Jr, Simpson JF (2003). “Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study.” Lancet 361 (9352): 125–9. doi:10.1016/S0140-6736(03)12230-1. PMID 12531579.
[12] Rosai Juan,Breast In: Rosai and Ackerman’s surgical pathology Volume-2, 10th Ed. Elsevier; 2012; 1695.

Chapter 6

[1] Berg JW, Hutter RV: Breast cancer. Cancer 1995; 75:257-269.
[2] Fisher ER, Gregorio RM: Fisher B, with the assistance of Redmond C, Vellios F, Sommers SC, and cooperating investigators. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol No. 4). Cancer 1975; 36:1-85.
[3] 676. Fisher ER, Palekar AS, Gregorio RM, Redmond C, Fisher B: Pathological findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). IV. Significance of tumor necrosis. Hum Pathol 1978; 9:523-530.
[4] Azzopardi JG, Laurini RN: Elastosis in breast cancer. Cancer 1974; 33:174-183.
[5] Fisher ER, Gregorio RM: Fisher B, with the assistance of Redmond C, Vellios F, Sommers SC, and cooperating investigators. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol No. 4). Cancer 1975; 36:1-85.
[6] Oberman HA: Invasive carcinoma of the breast with granulomatous response. Am J ClinPathol 1987; 88:718-721.
[7] Carstens PHB, Greenberg RA, Francis D, Lyon H: Tubular carcinoma of the breast. A long term follow-up. Histopathology 1985; 9:271-280.
[8] Deos PH, Norris HJ: Well-differentiated (tubular) carcinoma of the breast. A clinicopathologic study of 145 pure and mixed cases. Am J ClinPathol 1982; 78:1-7.
[9] Parl FF, Richardson LD: The histologic and biologic spectrum of tubular carcinoma of the breast. Hum Pathol 1983; 14:694-698.
[10] Bal A, Joshi K, Sharma SC, Das A, Verma A, Wig JD: Prognostic significance of micropapillary pattern in pure mucinous carcinoma of the breast. Int J SurgPathol 2008; 16:251-256.
[11] Walker RA: Mucoid carcinomas of the breast. A study using mucinhistochemistry and peanut lectin. Histopathology 1982; 6:571-579.
[12] Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM: Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J ClinOncol 1999; 17:1442-1448.
[13] Norris HJ, Taylor HB: Prognosis of mucinous (gelatinous) carcinoma of the breast. Cancer 1965; 18:879-885754.
[14] Rasmussen BB, Rose C, Christensen IB: Prognostic factors in primary mucinous breast carcinoma. Am J ClinPathol 1987; 87:155-160. 737.
[15] Clayton F: Pure mucinous carcinomas of breast. Morphologic features and prognostic correlates. Hum Pathol 1986; 17:34-38.
[16] Coyne JD, Irion L: Mammary mucinous cystadenocarcinoma. Histopathology 2006; 49:659-660.
[17] Koenig C, Tavassoli FA: Mucinous cystadenocarcinoma of the breast. Am J SurgPathol 1998; 22:698-703.
[18] Nassar H, Qureshi H, Volkanadsay N, Visscher D: Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J SurgPathol 2006; 30:501-5.
[19] Fisher ER, Palekar AS, Redmond C, Barton B, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). VI. Invasive papillary cancer. Am J ClinPathol 1980; 73:313-322.
[20] Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K, Sato Y, Aoyama H, Hayashi T, Kushima R: Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?. Hum Pathol 2008; 39:666-671.
[21] DelaCruz C, Moriya T, Endoh M, Watanabe M, Takeyama J, Yang M, Oguma M, Sakamoto K, Suzuki T, Hirakawa H, Orita Y, Ohuchi N, Sasano H: Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study. PatholInt 2004; 54:90-96.
[22] Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G: Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J ClinPathol 2004; 121:857-866.
[23] Kuroda N, Sugimoto T, Takahashi T, Moriki T, Toi M, Miyazaki E, Hiroi M, Enzan H: Invasive micropapillary carcinoma of the breast: an immunohistochemical study of neoplastic and stromal cells. Int J SurgPathol 2005; 13:51-55.
[24] DelaCruz C, Moriya T, Endoh M, Watanabe M, Takeyama J, Yang M, Oguma M, Sakamoto K, Suzuki T, Hirakawa H, Orita Y, Ohuchi N, Sasano H: Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study. PatholInt 2004; 54:90-96.
[25] Acs G, Esposito NN, Rakosy Z, Laronga C, Zhang PJ: Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol 2010; 34:1637-1646.
[26] Acs G, Paragh G, Chuang ST, Laronga C, Zhang PJ: The presence of micropapillary features and retraction artifact in core needle biopsy material predicts lymph node metastasis in breast carcinoma. Am J SurgPathol 2009; 33:202-210.
[27] Chen L, Fan Y, Lang RG, Guo XJ, Sun YL, Cui LF, Liu FF, Wei J, Zhang XM, Fu L: Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J SurgPathol 2008; 16:155-163.
[28] Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G: Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J ClinPathol 2004; 121:857-866.
[29] Abati AD, Kimmel M, Rosen PP: Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am J Clin Pathol 1990; 94:371-377.
[30] O’Malley FP, Bane A: An update on apocrine lesions of the breast. Histopathology 2008; 52:3-10.
[31] Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG: Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am J Pathol 1986; 123:532-541.
[32] Krausz T, Jenkins D, Grontoft O, Pollock DJ, Azzopardi JG: Secretory carcinoma of the breast in adults. Emphasis on late recurrence and metastasis. Histopathology 1989; 14:25-36.
[33] McDivitt RW, Stewart FW: Breast carcinoma in children. JAMA 1966; 195:388-390.
[34] Oberman HA: Secretory carcinoma of the breast in adults. Am J SurgPathol 1980; 4:465-470.
[35] Rosen PP, Cranor ML: Secretory carcinoma of the breast. Arch Pathol Lab Med 1991; 115:141-144.
[36] Tavassoli FA, Norris HJ: Secretory carcinoma of the breast. Cancer 1980; 45:2404-2413.
[37] Bussolati G, Papotti M, Sapino A, Gugliotta P, Ghiringhello B, Azzopardi JG: Endocrine markers in argyrophilic carcinomas of the breast. Am J SurgPathol 1987; 11:248-256.
[38] Cubilla AL, Woodruff JM: Primary carcinoid tumor of the breast. A report of eight patients. Am J SurgPathol 1977; 1:283-292.
[39] Nesland JM, Memoli VA, Holm R, Gould VE, Johannessen JV: Breast carcinomas with neuroendocrine differentiation. Ultrastruct Pathol 1985; 8:225-240.
[40] Pagani A, Papotti M, Hofler H, Weiler R, Winkler H, Bussolati G: Chromogranin A and B gene expression in carcinomas of the breast. Correlation of immunocytochemical, immunoblot, and hybridization analyses. Am J Pathol 1990; 136:319-327.
[41] Scopsi L, Balslev E, Brunner N, Poulsen HS, Andersen J, Rank F, Larsson LI: Immunoreactive opioid peptides in human breast cancer. Am J Pathol 1989; 134:473-479.
[42] Uccini S, Monardo F, Paradiso P, Masciangelo R, Marzullo A, Ruco LP, Baroni CD: Synaptophysin in human breast carcinomas. Histopathology 1991; 18:271-273.
[43] 866. Wilander E, Páhlman S, Sällström J, Lindgren A: Neuron-specific enolase expression and neuroendocrine differentiation in carcinomas of the breast. Arch Pathol Lab Med 1987; 111:830-832.
[44] Bauer TW, Rostock RA, Eggleston JC, Baral E: Spindle cell carcinoma of the breast. Four cases and review of the literature. Hum Pathol 1984; 15:147-152.
[45] Drudis T, Arroyo C, Van Hoeven K, Cordon-Cardo C, Rosen PP: The pathology of low-grade adenosquamous carcinoma of the breast. An immunohistochemical study. Pathol Annu 1994; 29(Pt 2):181-197.
[46] 922. Eusebi V, Lamovec J, Cattani MG, Fedeli F, Millis RR: Acantholytic variant of squamous-cell carcinoma of the breast. Am J Surg Pathol 1986; 10:855-861.
[47] Foschini MP, Fulcheri E, Baraechini P, Ceccarelli C, Betts CM, Eusebi V: Squamous cell carcinoma with prominent myxoidstroma. Hum Pathol 1990; 21:859-865.
[48] Gersell DJ, Katzenstein A-LA: Spindle cell carcinoma of the breast. A clinicopathologic and ultrastructural study. Hum Pathol 1981; 12:550-561.
[49] Ho BC, Tan HW, Lee VK, Tan PH: Preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast: potential diagnostic pitfalls. Histopathology 2006; 49:603-611.
[50] Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR: Management of inflammatory carcinoma of breast with combined modality approach. An update. Cancer 1981; 47:2537-2542.
[51] Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD: Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 1998; 82:2366-2372.
[52] Ashikari R, Park K, Huvos AG, Urban JA: Paget's disease of the breast. Cancer 1970; 26:680-685.
[53] Azzopardi JG, Eusebi V: Melanocyte colonization and pigmentation of breast carcinoma. Histopathology 1977; 1:21-30.

Chapter 7

[1] Pointon KS, Cunningham DA (August 1999). “Ultrasound findings in pure invasive lobular carcinoma of the breast: comparison with matched cases of invasive ductal carcinoma of the breast.” Breast 8 (4): 188–90. doi:10.1054/brst.1999.0042. PMID 14731438.
[2] Boughey JC, Wagner J, Garrett BJ, et al. (March 2009). “Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation.” Ann. Surg. Oncol. 16 (6): 1606–11. doi:10.1245/s10434-009-0402-z. PMID 19280264.
[3] Moore MM, Borossa G, Imbrie JZ, et al. (June 2000). “Association of Infiltrating Lobular Carcinoma With Positive Surgical Margins After Breast-Conservation Therapy.” Ann. Surg. 231 (6): 877–82. doi:10.1097/ 00000658-200006000-00012.PMC 1421077. PMID 10816631.
[4] Spencer JT, Shutter J (March 2009). “Synchronous bilateral invasive lobular breast cancer presenting as carcinomatosis in a male.” Am. J. Surg. Pathol. 33 (3): 470–4. doi:10.1097/PAS.0b013e318190d10d. PMID 19092630.
[5] Fletcher's diagnostic histopathology of tumors. 3rd Ed. p. 931-932.
[6] Arpino G, Bardou VJ, Clark GM, Elledge RM (2004). “Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.” Breast Cancer Res. 6 (3): R149–56. doi:10.1186/bcr767. PMC 400666. PMID 15084238.
[7] Varga Z, Mallon E. (Oct 2009). “Histology and Immunophenotype of Invasive Lobular Breast Cancer. Daily Practice and Pitfalls.” Breast Dis. 30: 15–19. doi:10.3233/BD-2009-0278. PMID 19850991.
[8] Rosai Juan,Breast In: Rosai and Ackerman’s surgical pathology Volume-2, 10th Ed. Elsevier; 2012; 1708-1709.
[9] Orell SR, Sterrett GF, et al; Breat In: Orell and Sterret’s Fine Needle Aspiration Cytology, 5th Ed. Elsevier; 2012; 193. Bloom HJG, Richardson WW.
[10] Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996;13:1919-1925.
[11] Nesland JM, Grode TH, Ottestad L, Johannesssen JV. Invasive.lobular carcinoma of the breast. The importance of an alveolar growth pattern. In: Rosen PP, Fechner RE, eds. Pathology Annual Vol. 23;1.Norwalk, CT: Appleton & Lange, 1992:233-247.
[12] Fisher ER, Gregorio RM, Redmond C, Fisher B. Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum Pathol 1977; 8:679-683.
[13] Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW. Infiltrating lobular carcinoma of the breast. Histopathology 1982;6: 149-161.
[14] Walford N, Ten Velden J. Histiocytoid breast carcinoma: an apocrine variant of lobular carcinoma. Histopathology 1989; 14:515-522.
[15] Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor ~howing apocrine differentiation. Hum PathoI 1992;23:655-662.

Chapter 8

[1] Farshid G, Balleine RL, Cummings M, Waring PKathleenCuningham Consortium for Research into Familial Breast Cancer (kConFab): Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol 2006; 30:1357-1366.
[2] Armes JE, Venter DJ: The pathology of inherited breast cancer. Pathology 2002; 34:309-314.
[3] Shousha S: Medullary carcinoma of the breast and BRCA1 mutation. Histopathology 2000; 37:182-185.
[4] Howell LP, Kline TS: Medullary carcinoma of the breast. An unusual cytologic finding in cyst fluid aspirates. Cancer 1990; 65:277-282.
[5] Ben-Ezra J, Sheibani K: Antigenic phenotype of the lymphocytic component of medullary carcinoma of the breast. Cancer 1987; 59:2037-2041.
[6] Gaffey MJ, Frierson Jr HF, Mills SE, Boyd JC, Zarbo RJ, Simpson JF, Gross LK, Weiss LM: Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance. Mod Pathol 1993; 6:721-728.
[7] Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S: Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 2005; 446:10-14.
[8] Yakirevich E, Ben Izhak O, Rennert G, Kovacs ZG, Resnick MB: Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol 1999; 12:1050-1056.
[9] Hsu S-M, Raine L, Nayak RN: Medullary carcinoma of breast. An immunohistochemical study of its lymphoid stroma. Cancer 1981; 48:1368-1376.
[10] Jensen ML, Kiaer H, Andersen J, Jensen V, Melsen F: Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology 1997; 30:523-532.
[11] Dwarakanath S, Lee AKC, DeLellis RA, Silverman ML, Frasca L, Wolfe HJ: S-100 protein positivity in breast carcinomas. A potential pitfall in diagnostic immunohistochemistry. Hum Pathol 1987; 18:1144-1148.
[12] Eichhorn JH: Medullary carcinoma, provocative now as then. Semin Diagn Pathol 2004; 21:65-73.
[13] Lazzaro B, Anderson AE, Kajdacsy-Balla A, Hessner MJ: Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem Mol Morphol 2001; 9:234-241.
[14] Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A: Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9:R24.
[15] Yazawa T, Kamma H, Ogata T: Frequent expression of HLA-DR antigen in medullary carcinoma of the breast. A possible reason for its prominent lymphocytic infiltration and favorable prognosis. ApplImmunohistochem 1993; 1:289-296.
[16] Bloom HJG, Richardson WW, Fields JR: Host resistance and survival in carcinoma of breasts. A study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br Med J 1970; 3:181-188.
[17] Richardson WW: Medullary carcinoma of the breast. A distinctive tumour type with a relatively good prognosis following radical mastectomy. Br J Cancer 1956; 10:415-423.
[18] Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V: Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up. Cancer 1977; 40:1365-1385.
[19] Racz MM, Pommier RF, Troxell ML. Fine needle aspiration cytology of medullary breast carcinoma: Report of 2 cases and review of literature with emphasis on differential diagnosis. DiagnCytopath 2007; 35:313-8.

Chapter 9

[1] Harris M, Persaud V: Carcinosarcoma of the breast. J Pathol 1974; 112:99-105.
[2] Tavassoli FA: Classification of metaplastic carcinomas of the breast. Pathol Annu 1992; 27(Pt 2):89-119.
[3] Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989; 64:1490-1499.
[4] Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ: Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol 2009; 33:534-541.
[5] Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989; 20:628-635.
[6] Eusebi V, Cattani MG, Ceccarelli C, Lamovec J: Sarcomatoid carcinomas of the breast. An immunohistochemical study of 14 cases. Progr Surg Pathol 1989; 10:83-100.
[7] Santeusanio G, Pascal RR, Bisceglia M, Costantino AM, Bosman C: Metaplastic breast carcinoma with epithelial phenotype of pseudosarcomatous components. Arch Pathol Lab Med 1988; 112:82-85.
[8] Carter MR, Hornick JL, Lester S, Fletcher CD: Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol 2006; 30:300-309.
[9] Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, Sneige N, Gilcrease MZ: Metaplasticsarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol 2005; 29:1456-1463.
[10] Kaufman MW, Marti JR, Gallager HS, Hoehn JL: Carcinoma of the breast with pseudosarcomatous metaplasia. Cancer 1984; 53:1908-1917.

Chapter 10

[1] Alis H, Yigitbas H, Kapan S, Kalayci M, Kilic G, Aygun E. Multifocal adenoid cystic carcinoma of the breast: an unusual presentation. Can J Surg. 2008;51(2): E36–E37.
[2] Law YM, Quek ST, Tan PH, Wong SL. Adenoid cystic carcinoma of the breast. Singapore Med J. 2009; 50 (1):8–11.
[3] Billroth T: Die Cylindergeschwalst. Untersuchungen ueber die Entwicklung der Blutgefefasse. Berlin: G Reimer; 1856:55-69.
[4] Arpino G, Clark GM, Mohsin S, Bardou VJ, Elledge RM: Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer 94(8):2119-27. Review. 2002 Apr 15.
[5] Kshirsagar AY, Wader JV, Langade YB, Jadhav KP, Zaware SU, Shekhar N. Adenoid cystic carcinoma of the male breast. Int Surg. 2006;91:234–6.
[6] Liu J, Jia W, Zeng Y, Deng H, Rao N, Su F. Adolescent male adenoid cystic breast carcinoma. Am Surg. 2012;78:E288–9.
[7] Miliauskas JR, Leong AS. Adenoid cystic carcinoma in a juvenile male breast. Pathology. 1991;23:298–301.
[8] Yoo SJ, Lee DS, Oh HS, Kim HJ, Kim MH, Ahn YC. Male breast adenoid cystic carcinoma. Case Rep Oncol. 2013;6(3):514–9.
[9] Woyke S, Domagala W, Obszewski W. Fine structure of mammary adenoid cystic carcinoma. Pol Med J. 1970;9:1140–8.
[10] Verani R, van der Bel-Kahn J. Mammary adenoid cystic carcinoma with unusual features. Am J Clin Pathol. 1973;59:653–8.
[11] Ferlito A, Dibonito L. Adenoid cystic carcinoma of the male breast, report of a case. Am Surg. 1974;40:72–6.
[12] Hjorth S, Magnusson PH, Blomquist P. Adenoid cystic carcinoma of the breast. Acta Chir Scand. 1977;143:155–8.
[13] Tang et al. Breast adenoid cystic carcinoma in a 19-year-old man: a case report and review of the literature. World Journal of Surgical Oncology (2015) 13:19 DOI 10.1186/s12957-015-0442-8.
[14] Anthony PP, James PD: Adenoid cystic carcinoma of the breast: prevalence, diagnostic criteria, and histogenesis. J Clin Pathol 1975, 28(8):647-55.
[15] Lusted D: Structural and growth patterns of adenoid cystic carcinoma of breast. Am J clin Pathol 1970, 54(3):419-25.
[16] Rosen PP. Adenoid cystic carcinoma. In: Rosen PP, ed. Rosen’s breast pathology. Philadelphia: Lippincott Williams and Wilkins, 2009:590e604.
[17] Bennett AK, Mills SE, Wick MR. Salivary-type neoplasms of the breast and lung. Semin Diagn Pathol 2003;20:279-304.
[18] Culubret M, Roig I: Fine needle aspiration biopsy of adenoid cystic carcinoma of the breast: a case report. Diagn Cytopathol 1996, 15(5):431-4.
[19] Stanley MW, Tani EM, Rutquist LE, Skoog L: Adenoid cystic carcinoma of the breast: diagnosis by fine needle aspiration. Diagn Cytopathol 1993, 9(2):184-7.
[20] Sachin B. Ingle, Nawab P. Jamadar, Baban D. Adgaonkar, Chitra R. Hinge (Ingle) and Saleha Siddiqui. An Interesting Pathological Diagnosis – Adenoid Cystic Carcinoma in an Adolescent Girl. Breast Cancer: Basicand Clinical Research 2015:9.
[21] Cavanzo FJ, Taylor HB: Adenoid cystic carcinoma of the breast. An analysis of 21 cases. Cancer 1969, 24(4):740-5.
[22] Ro JY, Silva EG, Gallager HS: Adenoid cystic carcinoma of the breast. Hum Pathol 1987, 18(12):1276-81. Review.
[23] McClenathan JH, de la Roza G: Adenoid cystic breast cancer. Am J Surg 2002, 183(6):646-9.
[24] Leeming R, Jenkins M, Mendelsohn G: Adenoid cystic carcinoma of the breast. Arch Surg 1992, 127(2):233-5. Review.
[25] Foschini MP, Reis-Filho JS, Eusebi V, et al. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol 2003;56:497e506.
[26] Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747e52.
[27] Di Palma S, Skalova A, Ungari M, et al. Pure salivary duct carcinomas can be classified into luminal, Her2 and basal-like phenotypes. Abstract 1072. Mod Pathol 2008;21(Suppl 1).
[28] Boujelbene N, Khabir A, Boujelbene N, Jeanneret Sozzi W, Mirimanoff RO, Khanfir K. Clinical review- breast adenoid cystic carcinoma. Breast.2012;21:124–7.
[29] Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–23.
[30] Miyai K, Schwartz MR, Divatia MK, Anton RC, Yong Wook P, Ayala AG, et al. Adenoid cystic carcinoma of breast: recent advances. World J Clin Cases. 2014;2(12):732–41.
[31] Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;15:2302–10.
[32] Peters GN, Wolff M. Adenoid cystic carcinoma of the breast. Report of 11 new cases: review of the literature and discussion of biological behaviour. Cancer. 1983;52:680–6.
[33] Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977–2006): a population-based cohort study. Breast Cancer Res. 2010; 12(4):R54.
[34] Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer. 2012;118:3945–53.

Chapter 11

[1] Sachin B Ingle, Chitra R Hinge (Ingle), Hemant G Murdeshwar, Baban D Adgaonkar. Unusual case of insitu (intracystic) papillary carcinoma of Breast. World J Clin Cases 2013 October 16; 1(7): 227-229.
[2] Anderson WF, Chu KC, Chang S, et al. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:1128–1135.
[3] Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology. 2008;52:20–29.
[4] Fayanju OM, Ritter J, Gillanders WE, et al. Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy. Am J Surg. 2007;194:497–500.
[5] Koerner F. Papilloma and papillary carcinoma. Semin Diagn Pathol. 2010;27:13–30.
[6] Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93:1046–1052.
[7] Louwman MW, Vriezen M, van Beek MW, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer. 2007;121:127–135.
[8] Pal SK, Lau SK, Kruper L, et al. Papillary carcinoma of the breast: an overview. Breast Cancer Res Treat. 2010;122:637–645.
[9] Solorzano CC, Middleton LP, Hunt KK, et al. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg. 2002;184:364–368.
[10] Ueng SH, Mezzetti T, Tavassoli FA. Papillary neoplasms of the breast: a review. Arch Pathol Lab Med. 2009;133:893–907.
[11] MacGrogan G, Moinfar F, Raju U. Pathology and genetics of tumors of the breast and female genital organs. In: Tavassoli FA Devilee P. World Health Organization Classification of Tumors. Lyon: IACR Press; 2003.
[12] Carter D, Orr SL, Merino MJ. Intracystic papillary carcinoma of the breast: after mastectomy, radiotherapy or excisional biopsy alone. Cancer. 1983;52:14–19.
[13] Rosen PP. Rosen’s Breast Pathology. Philadelphia: Lippincott Williams & Wilkins; 2009:423–449.
[14] Wei B, Bu H, Chen HJ, et al. Clinicopathologic study of solid papillary carcinoma of breast. Zhonghua Bing Li Xue Za Zhi. 2006;35:589–593.
[15] Calderaro J, Espie M, Duclos J, et al. Breast intracystic papillary carcinoma: an update. Breast J. 2009;15:639–644.
[16] Collins LC, Carlo VP, Hwang H, et al. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol. 2006;30:1002–1007.
[17] Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol. 2005;123:36–44.
[18] Laszio R, O'Brian ME, Relihan N, et al. Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: A case report and literature review. J Med Case Reports 2009;3: 13.
[19] Arora R, Gupta R, Sharma A, et al. Invasive papillary carcinoma of male breast. Ind J Pathol Microbiol 2010;53: 135-37.
[20] Dragoumis DM, Tsiftsoglou AP. Intracystic papillary carcinoma associated with ductal carcinoma in-situ in male breast. Images in Pathology 2008;54: 39-40.
[21] Grabowski J, Salzstein SL, Sadler GR, Blair S. Intracystic papillary carcinoma. Cancer. 2008;113(5):916–20.
[22] Russell (2000) Bailey and Love’s Short Practice of Surgery. In Chapter on breast cancer (23rdedn) Arnold, London.
[23] Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med 9: 208-221.
[24] Sabiston DC, Lyerly HK (1997) Sabiston textbook of surgery: The biological basis of modern surgical practice (fifteenth edn) Philadelphia, Pennsylvania: WB Saunders Company.
[25] Aguas F, Martins A, Gomes TP, de Sousa M, Silva DP; Portuguese Menopause Society and Portuguese Gynaecology Society (2005) Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer. Maturitas 52: S23-31.
[26] Murphy CE, Carder PJ, Lansdown MR, Speirs V (2006) Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 32: 44-47.
[27] Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26: 51-59.
[28] Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, et al. (2000) Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 113: 675-682.
[29] Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, et al. (1999) Phase II study of weekly intravenous Trastuzumab (Herceptin) in patients with HER-2/neu-overexpressing metastatic breast cancers. Seminars in oncology 26: 78-83.
[30] Malara NM, Leotta A, Sidoti A, Lio S, D’Angelo R, et al. (2006) Ageing, hormonal behaviour and cyclin D1 in ductal breast carcinomas. Breast 15: 81-89.
[31] Lerner LJ, Jordan VC (1990) Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 50: 4177-4189.
[32] Weinberg OK, Marquez-Garban DC, Pietras RJ (2005) New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat 8: 219-233.
[33] Kato S, Sato T, Watanabe T, Takemasa S, Masuhiro Y, et al. (2005) Function of nuclear sex hormone receptors in gene regulation. Cancer Chemother Pharmacol 56 Suppl 1: 4-9.
[34] Baykara M, Coskun U, Demirci U, Yildiz R, Benekli M, Cakir A and Buyukberber S (2010) Intracystic papillary carcinoma of the breast: one of the youngest patient in the literature. Med Oncol 27(4) 1427–8 DOI: 10.1007/s12032-009-9290-0.
[35] Umanah IN and Okpongette AS (2009) Intracystic papillary carcinoma of the breast in a 21-year old premenopausal Nigerian woman: a case report. Rare Tumors 1(2) e50 PMID: 21139929.
[36] Liberman L, Feng TL and Susnik B (2001) Case 35: intracystic papillary carcinoma with invasion. Radiology 219(3) 781–4 PMID: 11376269.
[37] . Dogan BE, Whitman GJ, Middleton LP et al. (2003) Intracystic papillary carcinoma of the breast. AJR Am J Roentgenol 181(1) 186 PMID: 12818855.
[38] Reefy S, Osman H, Chao C, Perry N and Mokbel K (2010) Surgical excision for B3 breast lesions diagnosed by vacuum-assisted core biopsy. Anticancer Res 30(6) 2287–90 PMID: 20651381.
[39] Yamamoto D, Ueda S, Senzaki H, Shoji T, Haijima H, Gondo H and Tanaka K (2001) New diagnostic approach to intracystic lesions of the breast by fiberoptic ductoscopy. Anticancer Res 21(6A) 4113–6.
[40] Mokbel K, Escobar PF and Matsunaga T (2005) Mammary ductoscopy: current status and future prospects. Eur J Surg Oncol 313–8 DOI: 10.1016/j.ejso.2004.10.004 PMID: 15642418.
[41] Tomonori K, Takayuki S, Tadahiko T, Hojo S, Akashi-Tanaka S, Murata Y. Clinical and pathological features of intracystic papillary carcinoma of the breast. Surgery Today. 2009; 39(1): 5–8.
[42] Benkaddour Y A, Hasnaoui S E, Fichtali K, Fakhir B, et al. Intracystic papillary carcinoma of the breast. Report of three cases and literature review. Case Rep Obstetr Gynecol. 2012, Article ID 979563.
[43] Kayahan M, Uzin M A, Ozkan O F, Gunes P, et al. Approach to papillary lesions of the breast (A Report of three cases). The J Breast Health. 2010; 6(4): 163-67.
[44] Rodriguez M C H, Secades A L, Angulo J M. Intracystic papillary carcinoma of the breast. Radiographics. 2010; 30:2021-2027.
[45] Esposito NN, Dabbs DJ, Bhargava R. Are encapsulated papillary carcinomas of the breast insitu or invasive? A basement membrane study of 27 cases. American Soc Clin Pathol. 2009; 131:228-242.
[46] Sara Al Reefy, Rashid Kameshki, Dhabya Al Sada, Abdullah Al Elewah, Arwa Al Awadhi, Kamil Al Awadhi. ecancer 2012;7:286-91.
[47] Noriko Yoshimura, Shigeru Murakami, Mayumi Kaneko, Akio Sakatani, Naoki Hirabayashi, and Wataru Takiyama, “Synchronous Bilateral Solid Papillary Carcinomas of the Breast,” Case Reports in Surgery 2013;1155:8121-29.
[48] Gruber et al: Measurement of tumor size with mammography, sonography and magnetic resonance imaging as compared to histological tumor size in primary breast cancer. BMC Cancer 2013;13:328-36.
[49] Irina Anca Eremia, Maria Ciobanu, Tenea T, Maria Victoria Comanescu, Stefania Craitoiu. Invasive papillary carcinoma of the mammary gland:histopathologic and immunohistochemical aspects. Rom J Morphol Embryol 2012;53(3):811-815.
[50] Terzi A, Uner AH. An unusual case of invasive papillary carcinoma of the breast. Indian J Pathol Microbiol 2012;55:543-5.
[51] Bhosale SJ, Kshirsagar AY, Sulhyan SR, Jagtap SV, Nikam YP. Case Rep Oncol 2010;3:410-415.
[52] Mulligan AM and O’Malley FP (2007) Metastatic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases. Int J Surg Pathol 15(2) 143–7 DOI: 10.1177/1066896906299119 PMID: 17478767.
[53] Fayanju OM, Ritter J, Gillanders WE, Eberlein TJ, Dietz JR, Aft R and Margenthaler JA (2007) Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy. Am J Surg194(4) 497–500,DOI: 10.1016/j.amjsurg.2007.06.016 PMID: 17826064.
[54] Mugler K, Marshal C, Hardesty L, Finlayson C and Singh M (2007) Intracystic papillary carcinoma of the breast: differential diagnosis and management. Oncology 21(7) 871–6 PMID: 17722745.
[55] Harris K, Faliakou E, Exon D, Nasiri N, Sacks NP and Gui GP (1999) Treatment and outcome of intracystic papillary carcinoma of the breast. Br J Surg 86 1274 DOI: 10.1046/j.1365-2168.1999.01254.x PMID: 10540131.

Chapter 12

[1] Fisher ER, Tavares J, Bulatao IS, Sass R, Fisher Bcollaborating NSABP investigators: Glycogen-rich, clear cell breast cancer. With comments concerning other clear cell variants. Hum Pathol 1985; 16:1085-1090.
[2] Hayes MMM, Seidman JD, Ashton MA: Glycogen-rich clear cell carcinoma of the breast. A clinicopathologic study of 21 cases. Am J Surg Pathol 1995; 19:904-911.
[3] Hull MT, Warfel KA: Glycogen-rich clear cell carcinomas of the breast. A clinicopathologic and ultrastructural study. Am J Surg Pathol 1986; 10:553-559.
[4] Tavassoli FA: Myoepithelial lesions of the breast. Myoepitheliosis, adenomyoepithelioma, and myoepithelial carcinoma. Am J Surg Pathol 1991; 15:554-568.
[5] Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, Pisters PW, Ballo MT, Chen L, Trent 3rd J, Burgess M, Patel S, Pollock RE, Cormier JN: Angiosarcoma of the breast. Cancer 2005; 104:2682-2688.
[6] Liberman L, Dershaw DD, Kaufman RJ, Rosen PP: Angiosarcoma of the breast. Radiology 1992; 183:649-654.
[7] Benda JA, Al-Jurf AS, Benson III AB: Angiosarcoma of the breast following segmental mastectomy complicated by lymphedema. Am J clin Pathol 1987; 87:651-655.
[8] Callery CD, Rosen PP, Kinne DW: Sarcoma of the breast. A study of 32 patients with reappraisal of classification and therapy. Ann Surg 1985; 201:527-532.
[9] Norris HJ, Taylor HB: Sarcomas and related mesenchymal tumors of the breast. Cancer 1968; 22:22-28.
[10] Donegan WL: Cancer of the breast in men. CA Cancer J Clin 1991; 41:339-354.
[11] El-Gazayerli M, Abdel-Aziz AS: On bilharziasis and male breast cancer in Egypt. A preliminary report and review of the literature. Br J Cancer 1963; 17:566-571.
[12] Sanchez AG, Villanueva AG, Redondo C: Lobular carcinoma of the breast in a patient with Klinefelter's syndrome. A case with bilateral, synchronous, histologically different breast tumors. Cancer 1986; 57:1181-1183.
[13] Cunha F, Andre S, Soares J: Morphology of male breast carcinoma in the evaluation of prognosis. Pathol Res Pract 1990; 186:745-750.

If you have any questions or comments with regards to this book, please fill out the form below. Thank you!

You have not viewed any product yet.